27 results on '"Joji Ishida"'
Search Results
2. The utility of DNA methylation analysis in elderly patients with pilocytic astrocytoma morphology
- Author
-
Yasuki Suruga, Kaishi Satomi, Yoshihiro Otani, Kentaro Fujii, Joji Ishida, Atsuhito Uneda, Nobushige Tsuboi, Keigo Makino, Shuichiro Hirano, Naoya Kemmotsu, Ryoji Imoto, Ryo Mizuta, Yusuke Tomita, Takao Yasuhara, Kana Washio, Hiroyuki Yanai, Yuko Matsushita, Yuko Hibiya, Akihiko Yoshida, David Capper, Koichi Ichimura, and Isao Date
- Subjects
Adult ,Aged, 80 and over ,Cancer Research ,Adolescent ,Brain Neoplasms ,Middle Aged ,DNA Methylation ,Astrocytoma ,Isocitrate Dehydrogenase ,Young Adult ,Neurology ,Oncology ,Child, Preschool ,Mutation ,Humans ,Neurology (clinical) ,Child ,Aged ,Retrospective Studies - Abstract
Pilocytic astrocytoma (PA) is a circumscribed low-grade astrocytic glioma, generally considered to be associated with a good prognosis. However, a subset of PA patients shows unfavorable outcomes. In this study, we retrospectively reviewed PA patients and performed further molecular analysis, such as DNA methylation profiling, to identify prognostic factors.We analyzed 29 histologically-confirmed PA patients from a single center from 2002 to 2021 and conducted integrated molecular analyses among elderly PA patients since age was an independent prognostic factor for poor outcomes.The median age at diagnosis was 14 years (range 3-82 years) and 4 patients (14%) were elderly (patients ≥ 60 years old). Age over 60 was associated with poor progression-free survival and overall survival. We performed DNA methylation analysis on 2 of the 4 elderly patients. Both cases were histologically diagnosed as PA, but DNA methylation profiling revealed one as high-grade astrocytoma with piloid features (all methylation class scores were below 0.3 in both v11b4 and v12.5) and the other as glioblastoma, IDH-wildtype (score was over 0.5 in both v11b4 and v12.5), using the German Cancer Research Center methylation profiling classifiers and t-SNE analysis.Elderly patients with PA morphology showed unfavorable outcomes in this cohort. In those patients, further molecular analysis and DNA methylation profiling revealed the possibility of high-grade astrocytic tumors, including newly defined entities.
- Published
- 2022
3. Modeling human brain tumors in flies, worms, and zebrafish: From proof of principle to novel therapeutic targets
- Author
-
Christian A. Smith, Hidehiro Okura, James T. Rutka, Madeline Hayes, Michael S. Taccone, Uswa Shahzad, Xi Huang, W. Brent Derry, Joji Ishida, Stacey Krumholtz, Julia Edgar, Kyle Gouveia, Sachin Kumar, Coco Mine, and Michael D. Taylor
- Subjects
Cancer Research ,High-throughput screening ,Cell ,Danio ,Review ,Computational biology ,Mice ,03 medical and health sciences ,0302 clinical medicine ,RNA interference ,medicine ,Animals ,Humans ,Caenorhabditis elegans ,Zebrafish ,030304 developmental biology ,0303 health sciences ,biology ,Brain Neoplasms ,biology.organism_classification ,3. Good health ,Drosophila melanogaster ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Neurology (clinical) ,Signal transduction ,Signal Transduction - Abstract
For decades, cell biologists and cancer researchers have taken advantage of non-murine species to increase our understanding of the molecular processes that drive normal cell and tissue development, and when perturbed, cause cancer. The advent of whole-genome sequencing has revealed the high genetic homology of these organisms to humans. Seminal studies in non-murine organisms such as Drosophila melanogaster, Caenorhabditis elegans, and Danio rerio identified many of the signaling pathways involved in cancer. Studies in these organisms offer distinct advantages over mammalian cell or murine systems. Compared to murine models, these three species have shorter lifespans, are less resource intense, and are amenable to high-throughput drug and RNA interference screening to test a myriad of promising drugs against novel targets. In this review, we introduce species-specific breeding strategies, highlight the advantages of modeling brain tumors in each non-mammalian species, and underscore the successes attributed to scientific investigation using these models. We conclude with an optimistic proposal that discoveries in the fields of cancer research, and in particular neuro-oncology, may be expedited using these powerful screening tools and strategies.
- Published
- 2020
4. Carotid-anterior cerebral artery (ACA) anastomosis associated with azygos ACA and ophthalmic artery arising from the middle meningeal artery: a case report
- Author
-
Naoko Saito, Akira Uchino, Koichiro Matsuura, Tomonari Suzuki, and Joji Ishida
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Anterior Cerebral Artery ,Middle meningeal artery ,Anastomosis ,Magnetic resonance angiography ,Pathology and Forensic Medicine ,Ophthalmic Artery ,03 medical and health sciences ,medicine.artery ,medicine ,Anterior cerebral artery ,Humans ,Radiology, Nuclear Medicine and imaging ,skin and connective tissue diseases ,0303 health sciences ,medicine.diagnostic_test ,business.industry ,Anatomic Variation ,food and beverages ,Right ophthalmic artery ,Meningeal Arteries ,eye diseases ,Cerebral Angiography ,stomatognathic diseases ,030301 anatomy & morphology ,Ophthalmic artery ,Surgery ,Radiology ,Anatomy ,Internal carotid artery ,business ,Carotid Artery, Internal ,Magnetic Resonance Angiography - Abstract
Among variations of the anterior cerebral artery (ACA), anastomosis of its A1-A2 junction with the ophthalmic segment of the internal carotid artery is rare and described as carotid-ACA anastomosis or infraoptic course of the ACA. One common variant, an azygos ACA, demonstrates no pairing of the A2 segment. To our knowledge, association of a carotid-ACA anastomosis with an azygos ACA is not reported in the English-language literature. We report a case diagnosed by magnetic resonance angiography in which right carotid-ACA anastomosis was associated with an azygos ACA and the right ophthalmic artery originated from the middle meningeal artery.
- Published
- 2019
5. Delayed postoperative hyponatremia after endoscopic transsphenoidal surgery for pituitary adenoma
- Author
-
Tomoko Sonoda, Joji Ishida, Masahiro Kameda, Tomotsugu Ichikawa, Takao Yasuhara, Fumio Otsuka, Kazuhiko Kurozumi, Yusuke Tomita, Kenichi Inagaki, and Isao Date
- Subjects
Adenoma ,Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Asymptomatic ,Gastroenterology ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Pituitary adenoma ,Internal medicine ,Prevalence ,polycyclic compounds ,medicine ,Humans ,Pituitary Neoplasms ,Neuronavigation ,Aged ,Transsphenoidal surgery ,business.industry ,technology, industry, and agriculture ,Endoscopy ,Odds ratio ,Middle Aged ,medicine.disease ,Confidence interval ,Mann–Whitney U test ,Female ,lipids (amino acids, peptides, and proteins) ,Surgery ,Neurology (clinical) ,Neurosurgery ,medicine.symptom ,Hyponatremia ,business ,030217 neurology & neurosurgery - Abstract
Hyponatremia generally occurs after transsphenoidal surgery (TSS) in a delayed fashion. Most patients with delayed postoperative hyponatremia (DPH) are asymptomatic or only express non-specific symptoms; consequently, DPH is associated with prolonged hospitalization. No consensus has been reached on which patients are at greatest risk of developing DPH. We reviewed patients with DPH and evaluated predictive factors for DPH. We retrospectively analyzed 107 consecutive patients who underwent endoscopic TSS for pituitary adenoma (January 2010–December 2016). Patients with DPH (hyponatremia group) and without DPH (normonatremia group) were compared according to their nadir sodium levels on postoperative days 3 to 10. We documented the patients’ demographics, clinical features, and postoperative physiological characteristics. Twenty-five (23.4%) patients developed DPH after endoscopic TSS. The patients’ mean age was 54 ± 17 years, and 63.6% of the patients were female. The overall prevalence of DPH was 23.4%. The non-parametric χ2 test and the Mann–Whitney U test revealed statistically significant differences in age, use of antihypertensive drugs, nonfunctioning pituitary adenoma, and higher yet normal preoperative thyroid-stimulating hormone level between the hyponatremia and normonatremia groups (P
- Published
- 2019
6. Differentiated glioblastoma cells accelerate tumor progression by shaping the tumor microenvironment via CCN1-mediated macrophage infiltration
- Author
-
Nobushige Tsuboi, Atsunori Kamiya, Kentaro Fujii, Yoshihiro Otani, Yusuke Tomita, Atsushi Fujimura, Yuji Matsumoto, Joji Ishida, Yasuhiko Hattori, Kazuhiko Kurozumi, Shuichiro Hirano, Yosuke Shimazu, Isao Date, Keigo Makino, and Atsuhito Uneda
- Subjects
Microenvironment ,Macrophage ,Differentiated glioblastoma cell ,Cell ,Biology ,lcsh:RC346-429 ,Pathology and Forensic Medicine ,Mice ,Cellular and Molecular Neuroscience ,Cell Line, Tumor ,Glioma ,Tumor Microenvironment ,Mesenchymal subtype ,medicine ,Animals ,Humans ,YAP/TAZ ,Glioblastoma stem cell ,lcsh:Neurology. Diseases of the nervous system ,Tumor microenvironment ,Brain Neoplasms ,Sequence Analysis, RNA ,TEAD ,Research ,Macrophages ,Mesenchymal stem cell ,Cell Differentiation ,medicine.disease ,Primary tumor ,Transplantation ,medicine.anatomical_structure ,Tumor progression ,Disease Progression ,Cancer research ,Female ,Neurology (clinical) ,Glioblastoma ,CCN1 ,Cysteine-Rich Protein 61 - Abstract
Glioblastoma (GBM) is the most lethal primary brain tumor characterized by significant cellular heterogeneity, namely tumor cells, including GBM stem-like cells (GSCs) and differentiated GBM cells (DGCs), and non-tumor cells such as endothelial cells, vascular pericytes, macrophages, and other types of immune cells. GSCs are essential to drive tumor progression, whereas the biological roles of DGCs are largely unknown. In this study, we focused on the roles of DGCs in the tumor microenvironment. To this end, we extracted DGC-specific signature genes from transcriptomic profiles of matched pairs of in vitro GSC and DGC models. By evaluating the DGC signature using single cell data, we confirmed the presence of cell subpopulations emulated by in vitro culture models within a primary tumor. The DGC signature was correlated with the mesenchymal subtype and a poor prognosis in large GBM cohorts such as The Cancer Genome Atlas and Ivy Glioblastoma Atlas Project. In silico signaling pathway analysis suggested a role of DGCs in macrophage infiltration. Consistent with in silico findings, in vitro DGC models promoted macrophage migration. In vivo, coimplantation of DGCs and GSCs reduced the survival of tumor xenograft-bearing mice and increased macrophage infiltration into tumor tissue compared with transplantation of GSCs alone. DGCs exhibited a significant increase in YAP/TAZ/TEAD activity compared with GSCs. CCN1, a transcriptional target of YAP/TAZ, was selected from the DGC signature as a candidate secreted protein involved in macrophage recruitment. In fact, CCN1 was secreted abundantly from DGCs, but not GSCs. DGCs promoted macrophage migration in vitro and macrophage infiltration into tumor tissue in vivo through secretion of CCN1. Collectively, these results demonstrate that DGCs contribute to GSC-dependent tumor progression by shaping a mesenchymal microenvironment via CCN1-mediated macrophage infiltration. This study provides new insight into the complex GBM microenvironment consisting of heterogeneous cells.
- Published
- 2021
7. Histopathology and prognosis of germ cell tumors metastatic to brain: cohort study
- Author
-
Joji Ishida, Caterina Giannini, Avital Perry, Masao Matsutani, Christopher S. Graffeo, Yoshitaka Narita, Makoto Ohno, Nobuhito Saito, David J. Daniels, Hirokazu Takami, Ryo Nishikawa, Yoichi Nakazato, Koichi Ichimura, Takami H., Graffeo C.S., Perry A., Ohno M., Ishida J., Giannini C., Narita Y., Nakazato Y., Saito N., Nishikawa R., Matsutani M., Ichimura K., and Daniels D.J.
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Adolescent ,Metastasi ,Gastroenterology ,Metastasis ,Embryonal carcinoma ,Cohort Studies ,Young Adult ,Internal medicine ,medicine ,Dysgerminoma ,Germ cell tumor ,Humans ,business.industry ,Brain Neoplasms ,Mediastinum ,Seminoma ,Middle Aged ,Neoplasms, Germ Cell and Embryonal ,medicine.disease ,Prognosis ,medicine.anatomical_structure ,Neurology ,Oncology ,Histopathology ,Female ,Neurology (clinical) ,Germ cell tumors ,business ,Brain metastasis - Abstract
Introduction: Germ cell tumors (GCTs) are uncommon neoplasms predominantly arising in midline tissues. The prognostic significance of histopathology in predicting metastatic GCT behavior is poorly understood. Methods: Multicenter international cohort study including 29 patients with GCTs metastatic to brain were retrospectively investigated (18 patients from Mayo Clinic and 11 patients from the intracranial germ cell tumor genome analysis consortium in Japan). Clinical characteristics were analyzed using the Chi-square test (two-tailed) for categorical variables and using the log-rank test for survival data. Results: Median age at treatment was 31years (range 14–58). Primary disease sites were testis (71%), mediastinum (18%), and female reproductive organs (11%). Median metastatic interval was 223days (range, 6–6124). Median follow-up was 346days (range, 1–5356), with 16 deaths (57%) occurring after the median overall survival of 455days. Actuarial one-year survival was 51%; 12-of-16 deaths (75%) were attributed to intracranial disease. Appearance of the same GCT subtype at the metastatic site as the primary was high for non-seminomatous GCT (NSGCT, 64–100%), but low for seminoma/dysgerminoma and mature teratoma (MT, 14, 17%, respectively). Gain of a new component was seen in 4 (20%)—3 of which included embryonal carcinoma (EC) at the primary site (75%). Incidence of cases without seminoma/dysgerminoma increased significantly after metastasis (p = 0.02). Metastatic interval was shorter in cases with histological change (199 vs 454days, p = 0.009). Overall survival was associated with MT primary histopathology (p = 0.02). Conclusion: Histological differentiation at the primary GCT site influences metastatic prognosis. Aggressive behavior is associated with NSGCT, while EC frequently demonstrates multi-directional histological differentiation after brain metastasis, and such histological dynamism is associated with shorter metastatic interval. Most metastases occurred within one year of diagnosis, emphasizing the need for close surveillance in newly diagnosed extra-cranial GCT.
- Published
- 2021
8. MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma
- Author
-
Brian Golbourn, Naohide Fujita, Andrew Bondoc, Nesrin Sabha, Christian A. Smith, Kristina Mikloska, Saira Alli, James T. Rutka, Stacey Krumholtz, Amanda Luck, Joji Ishida, Colin Maslink, Dilakshan Srikanthan, and Kullervo Hynynen
- Subjects
medicine.medical_treatment ,Pharmaceutical Science ,02 engineering and technology ,Blood–brain barrier ,03 medical and health sciences ,Mice ,Drug Delivery Systems ,Glioma ,medicine ,Animals ,Brain Stem Neoplasms ,Humans ,Doxorubicin ,030304 developmental biology ,0303 health sciences ,Chemotherapy ,business.industry ,Diffuse Intrinsic Pontine Glioma ,021001 nanoscience & nanotechnology ,medicine.disease ,Magnetic Resonance Imaging ,Pons ,3. Good health ,medicine.anatomical_structure ,Pharmaceutical Preparations ,Drug delivery ,Microbubbles ,Cancer research ,Brainstem ,0210 nano-technology ,business ,medicine.drug - Abstract
Diffuse intrinsic pontine glioma (DIPG) is a surgically unresectable and devasting tumour in children. To date, there are no effective chemotherapeutics despite a myriad of clinical trials. The intact blood-brain barrier (BBB) is likely responsible for the limited clinical response to chemotherapy. MRI-guided focused ultrasound (MRgFUS) is a promising non-invasive method for treating CNS tumours. Moreover, MRgFUS allows for the temporary and repeated disruption of the BBB. Our group previously reported the feasibility of temporary BBB opening within the normal murine brainstem using MRgFUS following intravenous (IV) administration of microbubbles. In the current study, we set out to test the effectiveness of targeted chemotherapy when paired with MRgFUS in murine models of DIPG. Doxorubicin was selected from a drug screen consisting of conventional chemotherapeutics tested on patient-derived cell lines. We studied the RCAS/Tv-a model where RCAS-Cre, RCAS-PDGFB, and RCAS-H3.3K27M were used to drive tumourigenesis upon injection in the pons. We also used orthotopically injected SU-DIPG-6 and SU-DIPG-17 xenografts which demonstrated a diffusely infiltrative tumour growth pattern similar to human DIPG. In our study, SU-DIPG-17 xenografts were more representative of human DIPG with an intact BBB. Following IV administration of doxorubicin, MRgFUS-treated animals exhibited a 4-fold higher concentration of drug within the SU-DIPG-17 brainstem tumours compared to controls. Moreover, the volumetric tumour growth rate was significantly suppressed in MRgFUS-treated animals whose tumours also exhibited decreased Ki-67 expression. Herein, we provide evidence for the ability of MRgFUS to enhance drug delivery in a mouse model of DIPG. These data provide critical support for clinical trials investigating MRgFUS-mediated BBB opening, which may ameliorate DIPG chemotherapeutic approaches in children.
- Published
- 2020
9. Fibroblast growth factor 13 regulates glioma cell invasion and is important for bevacizumab-induced glioma invasion
- Author
-
Joji Ishida, Atsuhito Uneda, Yoshihiro Otani, Tomotsugu Ichikawa, Yuji Matsumoto, Yasuhiko Hattori, Hiroyuki Michiue, Tetsuo Oka, Toshihiko Shimizu, Kazuhiko Kurozumi, Yousuke Tomita, Satoshi Inoue, and Isao Date
- Subjects
0301 basic medicine ,Cancer Research ,Angiogenesis ,Cell ,Apoptosis ,Mice, SCID ,Biology ,Fibroblast growth factor ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Cell Movement ,Glioma ,Biomarkers, Tumor ,Tumor Cells, Cultured ,Genetics ,medicine ,Animals ,Humans ,Neoplasm Invasiveness ,neoplasms ,Molecular Biology ,Cell Proliferation ,Brain Neoplasms ,Cell growth ,Prognosis ,medicine.disease ,Xenograft Model Antitumor Assays ,nervous system diseases ,Bevacizumab ,Fibroblast Growth Factors ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,medicine.anatomical_structure ,Cell culture ,030220 oncology & carcinogenesis ,Neoplastic Stem Cells ,Cancer research ,Female ,Stem cell ,Glioblastoma ,Intracellular ,Follow-Up Studies - Abstract
Glioblastoma has the poorest prognosis, and is characterized by excessive invasion and angiogenesis. To determine the invasive mechanisms, we previously used two glioma cell lines (J3T-1 and J3T-2) with different invasive phenotypes. The J3T-1 showed abundant angiogenesis and tumor cell invasion around neovasculature, while J3T-2 showed diffuse cell infiltration into surrounding healthy parenchyma. Microarray analyses were used to identify invasion-related genes in J3T-2 cells, and the expressed genes and their intracellular and intratumoral distribution patterns were evaluated in J3T-2 cell lines, human glioma cell lines, human glioblastoma stem cells and human glioblastoma specimens. To determine the role of the invasion-related genes, invasive activities were evaluated in vitro and in vivo. Fibroblast growth factor 13 (FGF13) was overexpressed in J3T-2 cells compared to J3T-1 cells, and in human glioma cell lines, human glioblastoma stem cells and human glioblastoma specimens, when compared to that of normal human astrocytes. Immunohistochemical staining and the RNA-seq (sequencing) data from the IVY Glioblastoma Atlas Project showed FGF13 expression in glioma cells in the invasive edges of tumor specimens. Also, the intracellular distribution was mainly in the cytoplasm of tumor cells and colocalized with tubulin. Overexpression of FGF13 stabilized tubulin dynamics in vitro and knockdown of FGF13 decreased glioma invasion both in vitro and in vivo and prolonged overall survival of several xenograft models. FGF13 was negatively regulated by hypoxic condition. Silencing of FGF13 also decreased in vivo bevacizumab-induced glioma invasion. In conclusion, FGF13 regulated glioma cell invasion and bevacizumab-induced glioma invasion, and could be a novel target for glioma treatment.
- Published
- 2017
10. High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene
- Author
-
Koichi Ichimura, Takashi Kohno, Yoshiko Nakano, Hiroyuki Yanai, Akira Shimada, Junko Hirato, Masatomo Doi, Kana Washio, Takehiro Tanaka, Isao Date, Akihiko Yoshida, Joji Ishida, and Kazuhiko Kurozumi
- Subjects
Cancer Research ,medicine.medical_specialty ,Pathology ,Neurology ,Adolescent ,Oncogene Proteins, Fusion ,medicine.medical_treatment ,Oligodendroglioma ,Targeted therapy ,Fusion gene ,03 medical and health sciences ,0302 clinical medicine ,Edema ,medicine ,Meningeal Neoplasms ,Humans ,Receptor, trkA ,Gene ,Craniotomy ,Kinase ,business.industry ,Brain Neoplasms ,General Medicine ,Glioma ,Oncology ,Chromosomes, Human, Pair 1 ,030220 oncology & carcinogenesis ,Mutation ,Female ,Neurology (clinical) ,Guanine nucleotide exchange factor ,medicine.symptom ,Chromosome Deletion ,Gene Fusion ,business ,Chromosomes, Human, Pair 19 ,030217 neurology & neurosurgery ,Rho Guanine Nucleotide Exchange Factors - Abstract
Here, we report a highly unusual case of high-grade glioneuronal tumor with a neurotrophic tropomyosin receptor kinase (NTRK) fusion gene. A 13-year-old girl presented with headache and vomiting and MRI detected two cystic lesions bilaterally in the frontal areas with surrounding edema. The left larger tumor was removed by left frontal craniotomy. The tumor was diagnosed as a high-grade glioneuronal tumor, unclassified. Methylation profiling classified it as a diffuse leptomeningeal glioneuronal tumor (DLGNT) with low confidence. This tumor showed genotypes frequently found in DLGNT such as 1p/19q codeletion without IDH mutation and, however, did not have the typical DLGNT clinical and histological features. RNA sequencing identified an ARHGEF2 (encoding Rho/Rac guanine nucleotide exchange factor 2)-NTRK1 fusion gene. The presence of recurrent NTRK fusion in glioneuronal tumors has an important implication in the clinical decision making and opens up a possibility of novel targeted therapy.
- Published
- 2019
11. [Cilengitide]
- Author
-
Kazuhiko, Kurozumi, Joji, Ishida, Tomotsugu, Ichikawa, and Isao, Date
- Subjects
Brain Neoplasms ,Humans ,Snake Venoms - Published
- 2019
12. [Molecular targeted drugs in gliomas]
- Author
-
Kazuhiko, Kurozumi, Joji, Ishida, Tomotsugu, Ichikawa, and Isao, Date
- Subjects
Brain Neoplasms ,Humans ,Glioma ,Molecular Targeted Therapy - Published
- 2019
13. Perioperative Management Center (PERIO) for Neurosurgical Patients
- Author
-
Machiko Sato, Tomotsugu Ichikawa, Yoshikazu Matsuoka, Masafumi Hiramatsu, Yoshihiko Soga, Reiko Yamanaka, Masahiro Kameda, Ayasa Misaki, Aiko Shinko, Tomohito Hishikawa, Hiroshi Morimatsu, Yasuko Hashimoto, Kazuhiko Kurozumi, Joji Ishida, Yuriko Ishihara, Takao Yasuhara, Takako Ashiwa, Takashi Agari, Akemi Arioka, Toshihiro Sasaki, Isao Date, and Motomu Kobayashi
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Hospital Departments ,complication ,Neurosurgical Procedures ,Perioperative Care ,rehabilitation ,Pulmonary function testing ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Humans ,030212 general & internal medicine ,Retrospective Studies ,Patient Care Team ,Rehabilitation ,Perioperative management ,business.industry ,perioperative management ,Retrospective cohort study ,030206 dentistry ,Perioperative ,cancellation of surgery ,Surgery ,Hospitalization ,preoperative evaluation ,Original Article ,Neurology (clinical) ,Neurosurgery ,Complication ,business ,Blood sampling - Abstract
Perioperative management is critical for positive neurosurgical outcomes. In order to maintain safe and authentic perioperative management, a perioperative management center (PERIO) was introduced to patients of our Neurosurgery Department beginning in June 2014. PERIO involves a multidisciplinary team consisting of anesthesiologists, dentists/dental hygienists/technicians, nurses, physical therapists, pharmacists, and nutritionists. After neurosurgeons decide on the course of surgery, a preoperative evaluation consisting of blood sampling, electrocardiogram, chest X-ray, and lung function test was performed. The patients then visited the PERIO clinic 7–14 days before surgery. One or two days before surgery, the patients without particular issues enter the hospital and receive a mouth cleaning one day before surgery. After surgery, postoperative support involving eating/swallowing evaluation, rehabilitation, and pain control is provided. The differences in duration from admission to surgery, cancellation of surgery, and postoperative complications between PERIO and non-PERIO groups were examined. Eighty-five patients were enrolled in the PERIO group and 131 patients in the non-PERIO group. The duration from admission to surgery was significantly decreased in the PERIO group (3.6 ± 0.3 days), compared to that in the non-PERIO group (4.7 ± 0.2 days). There was one cancelled surgery in the PERIO group and six in the non-PERIO group. Postoperative complications and the overall hospital stay did not differ between the two groups. The PERIO system decreased the duration from admission to surgery, and it is useful in providing high-quality medical service, although the system should be improved so as not to increase the burden on medical staff.
- Published
- 2016
14. δ-Catenin Promotes Bevacizumab-Induced Glioma Invasion
- Author
-
Atsuhito Uneda, Yuji Matsumoto, Yusuke Tomita, Yoshihiro Otani, Tetsuo Oka, Isao Date, Yasuhiko Hattori, Kazuhiko Kurozumi, Toshihiko Shimizu, Joji Ishida, and Tomotsugu Ichikawa
- Subjects
0301 basic medicine ,Cancer Research ,Delta Catenin ,genetic structures ,Bevacizumab ,Angiogenesis ,Cell ,Mice, Nude ,Angiogenesis Inhibitors ,Transfection ,03 medical and health sciences ,Mice ,Rats, Nude ,0302 clinical medicine ,Downregulation and upregulation ,In vivo ,Cell Movement ,Glioma ,Cell Line, Tumor ,medicine ,Cytotoxic T cell ,Animals ,Humans ,Neoplasm Invasiveness ,RNA, Small Interfering ,Mice, Inbred BALB C ,Temozolomide ,business.industry ,Brain Neoplasms ,Catenins ,medicine.disease ,Xenograft Model Antitumor Assays ,eye diseases ,Rats ,Gene Expression Regulation, Neoplastic ,Survival Rate ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Gene Knockdown Techniques ,Cancer research ,business ,medicine.drug - Abstract
The combination of bevacizumab with temozolomide and radiotherapy was shown to prolong progression-free survival in newly diagnosed patients with glioblastoma, and this emphasizes the potential of bevacizumab as a glioma treatment. However, although bevacizumab effectively inhibits angiogenesis, it has also been reported to induce invasive proliferation. This study examined gene expression in glioma cells to investigate the mechanisms of bevacizumab-induced invasion. We made a human glioma U87ΔEGFR cell xenograft model by stereotactically injecting these cells into the brain of animals. We administered bevacizumab intraperitoneally three times per week. At 18 days after tumor implantation, the brains were removed for histopathology and mRNA was extracted. In vivo, bevacizumab treatment increased glioma cell invasion. qRT-PCR array analysis revealed upregulation of δ-catenin (CTNND2) and several other factors. In vitro, bevacizumab treatment upregulated δ-catenin expression. A low concentration of bevacizumab was not cytotoxic, but tumor cell motility was increased in scratch wound assays and two-chamber assays. Overexpression of δ-catenin increased the tumor invasion in vitro and in vivo. However, δ-catenin knockdown decreased glioma cell invasiveness. The depth of tumor invasion in the U87ΔEGFR cells expressing δ-catenin was significantly increased compared with empty vector-transfected cells. The increase in invasive capacity induced by bevacizumab therapy was associated with upregulation of δ-catenin expression in invasive tumor cells. This finding suggests that δ-catenin is related to tumor invasion and migration.
- Published
- 2018
15. Comparative Histologic and Molecular Analysis of 2 Recurrent Lesions Showing Different Magnetic Resonance Imaging Responses After Bevacizumab Treatment: Report of a Case of Anaplastic Astrocytoma
- Author
-
Kazuhiko Kurozumi, Isao Date, Yoshihiro Otani, Tomotsugu Ichikawa, Joji Ishida, and Atsuhito Uneda
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Bevacizumab ,Angiogenesis ,Astrocytoma ,Lesion ,03 medical and health sciences ,0302 clinical medicine ,Antineoplastic Agents, Immunological ,Cerebellar hemisphere ,Biopsy ,medicine ,Humans ,medicine.diagnostic_test ,business.industry ,Brain Neoplasms ,Magnetic resonance imaging ,medicine.disease ,Magnetic Resonance Imaging ,Treatment Outcome ,030220 oncology & carcinogenesis ,Cerebellar vermis ,Surgery ,Neurology (clinical) ,medicine.symptom ,business ,Glioblastoma ,030217 neurology & neurosurgery ,medicine.drug ,Anaplastic astrocytoma - Abstract
Background We report the case of a patient with anaplastic astrocytoma whose 2 recurrent lesions showed different imaging responses from one another after bevacizumab treatment. Histologic and genetic features of this patient are also described. Case Description A 31-year-old patient with left temporal anaplastic astrocytoma had surgery, local radiotherapy, and chemotherapy. Recurrent lesions appeared in the cerebellar vermis and left cerebellar hemisphere, and the patient was started on biweekly bevacizumab. Subsequently, the 2 enhanced lesions showed different response patterns on magnetic resonance imaging. Although the lesion in the cerebellar vermis showed an enlargement of enhancing mass, the lesion in the left cerebellar hemisphere showed disappearance of enhancement. We resected the cerebellar vermis lesion and performed biopsy on the cerebellar hemisphere lesion. The specimens were investigated. Both recurrent lesions showed higher Ki-67 labeling indices and pericyte proliferation, and less angiogenesis compared with the initial specimen. Transmission electron microscopy showed a reduction in the distance between the endothelial cells and tumor cells in both recurrent lesions, compared with the initial lesion. However, the tight junctions in the vermian lesion were still disrupted compared with the initial lesion and the cerebellar hemispheric lesion. Genetic analysis of the initial specimen showed proneural signature; however, the recurrent vermian lesion exhibited decreased expression of proneural markers. Conclusions We report a case of anaplastic astrocytoma with 2 different imaging responses to bevacizumab. Our analysis suggests that differences in tight junctions possibly contributed to the changes on magnetic resonance imaging observed after bevacizumab treatment.
- Published
- 2018
16. Evaluation of extracellular matrix protein CCN1 as a prognostic factor for glioblastoma
- Author
-
Joji Ishida, Toshihiko Shimizu, Kentaro Fujii, Tetsuo Oka, Kazuhiko Kurozumi, Manabu Onishi, Tomotsugu Ichikawa, Yoshihiro Otani, Isao Date, and Yosuke Shimazu
- Subjects
Adult ,Male ,Cancer Research ,Pathology ,medicine.medical_specialty ,Methyltransferase ,Angiogenesis ,Integrin ,Gene Expression ,Extracellular matrix ,O(6)-Methylguanine-DNA Methyltransferase ,Young Adult ,Glioma ,Biomarkers, Tumor ,Humans ,Medicine ,Aged ,Proportional Hazards Models ,Aged, 80 and over ,biology ,Brain Neoplasms ,business.industry ,Cell growth ,Hazard ratio ,General Medicine ,Middle Aged ,Prognosis ,medicine.disease ,Immunohistochemistry ,Survival Rate ,Oncology ,biology.protein ,Female ,Neurology (clinical) ,Glioblastoma ,business ,Cysteine-Rich Protein 61 - Abstract
Recently, research efforts in identifying prognostic molecular biomarkers for malignant glioma have intensified. Cysteine-rich protein 61 (CCN1) is one of the CCN family of matricellular proteins that promotes cell growth and angiogenesis in cancers through its interaction with several integrins. In this study, we investigated the relationships among CCN1, O(6)-methylguanine-DNA methyltransferase expression, the tumor removal rate, and prognosis in 46 glioblastoma patients treated at the Okayama University Hospital. CCN1 expression was high in 31 (67 %) of these patients. The median progression-free survival (PFS) and overall survival (OS) times of patients with high CCN1 expression was significantly shorter than those of patients with low CCN1 expression (p 0.005). In a multivariate Cox analysis, CCN1 proved to be an independent prognostic factor for patient survival [PFS, hazard ratio (HR) = 3.53 (1.55-8.01), p = 0.003 and OS, HR = 3.05 (1.35-6.87), p = 0.007]. Moreover, in the 31 patients who underwent gross total resection, the PFS and OS times of those with high CCN1 expression were significantly shorter than those with low CCN1 expression. It was concluded that CCN1 might emerge as a significant prognostic factor regarding the prognosis of glioblastoma patients.
- Published
- 2015
17. Reduced neurotoxicity with combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) and deferred radiotherapy for primary central nervous system lymphoma
- Author
-
Kazuhiko Kurozumi, Isao Date, Hiroyuki Michiue, Eisei Kondo, Akihiro Kawasaki, Joji Ishida, Yoshinobu Maeda, and Tomotsugu Ichikawa
- Subjects
Male ,medicine.medical_specialty ,Vincristine ,Lymphoma ,genetic structures ,Cyclophosphamide ,Prednisolone ,medicine.medical_treatment ,Kaplan-Meier Estimate ,Neuropsychological Tests ,CHOP ,Gastroenterology ,Disease-Free Survival ,Central Nervous System Neoplasms ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,polycyclic compounds ,medicine ,Humans ,Karnofsky Performance Status ,Aged ,business.industry ,Primary central nervous system lymphoma ,Neurotoxicity ,General Medicine ,Middle Aged ,medicine.disease ,Survival Analysis ,eye diseases ,Surgery ,Radiation therapy ,Methotrexate ,Treatment Outcome ,Doxorubicin ,Female ,Neurology (clinical) ,business ,medicine.drug - Abstract
Objective Although high-dose methotrexate and whole-brain radiation therapy (WBRT) is the current standard for primary central nervous system lymphoma (PCNSL), it has a limited response rate and produces radiation-induced neurotoxicity. We report the effect of a combined treatment of high-dose methotrexate, cyclophosphamide, doxorubicin, vincristine and prednisolone (M-CHOP) for immunocompetent patients with PCNSL. Methods We analyzed 24 patients who had received M-CHOP administered in 28-day cycles with or without WBRT. The response rate to M-CHOP, overall survival (OS), and recurrence-free survival (RFS) were analyzed. Results Nine patients were treated with M-CHOP plus WBRT and 15 patients were treated with M-CHOP alone. Twenty-one patients achieved a complete response and three patients achieved a partial response to M-CHOP, for a 100% response rate. With a median follow-up of 70 months, the median OS and RFS were 33 and 13 months, respectively. The median OS for patients treated with M-CHOP plus WBRT and M-CHOP alone was 33 and 32 months, respectively. Of the 13 patients whose age was above 65 years, the median OS for the M-CHOP plus WBRT group (two patients) and the M-CHOP alone group (11 patients) was 14 and 32 months, respectively. Toxicities related to M-CHOP were mostly hematologic and generally mild to moderate. Two patients whose age was above 65 years in the M-CHOP plus WBRT group developed neurotoxicity. Conclusion Combined treatment with M-CHOP was well tolerated and produced a high response rate. Deferring WBRT was associated with reduced neurotoxicity without worsening the prognosis, especially in elderly patients.
- Published
- 2014
18. Integrin antagonist augments the therapeutic effect of adenovirus-mediated REIC/Dkk-3 gene therapy for malignant glioma
- Author
-
Tomotsugu Ichikawa, Tetsuo Oka, Joji Ishida, Isao Date, Yasutomo Nasu, Kazuhiko Kurozumi, Manabu Onishi, Yousuke Shimazu, Masami Watanabe, Hiromi Kumon, and Kentaro Fujii
- Subjects
Integrins ,Combination therapy ,Genetic enhancement ,Mice, Nude ,Antineoplastic Agents ,Apoptosis ,Biology ,Peptides, Cyclic ,Adenoviridae ,Viral vector ,Transduction, Genetic ,In vivo ,Cell Line, Tumor ,Glioma ,Genetics ,medicine ,Animals ,Humans ,Molecular Biology ,Adaptor Proteins, Signal Transducing ,Caspase 8 ,Mice, Inbred BALB C ,Brain Neoplasms ,Cell growth ,Genetic Therapy ,medicine.disease ,Combined Modality Therapy ,Xenograft Model Antitumor Assays ,Caspase 9 ,Astrocytes ,Gene Knockdown Techniques ,Cancer research ,Intercellular Signaling Peptides and Proteins ,Molecular Medicine ,Female ,Chemokines ,Immortalised cell line ,Snake Venoms - Abstract
Reduced expression in immortalized cells/Dickkopf-3 (REIC/Dkk-3) was identified as a gene whose expression is reduced in many human cancers. REIC/Dkk-3 expression is also downregulated in malignant glioma and regulates cell growth through caspase-dependent apoptosis. cRGD (EMD121974), an antagonist of integrins, has demonstrated preclinical efficacy against malignant glioma. In this study, we investigated the antiglioma effect of combination therapy using an adenovirus vector carrying REIC/Dkk-3 (Ad-REIC) and cRGD. Quantitative real-time reverse-transcription PCR revealed the reduction of REIC/Dkk-3 mRNA levels in malignant glioma cell lines. The reduction of REIC/Dkk-3 protein expression in malignant glioma cell lines was also confirmed with western blot analysis. After treatment with Ad-REIC and cRGD, the proliferative rate of malignant glioma cells was significantly reduced in a time-dependent manner. In vivo, there was a statistically significant increase in the survival of mice treated with Ad-REIC and cRGD combination therapy compared with Ad-REIC monotherapy. We identified an apoptotic effect following monotherapy with Ad-REIC. Moreover, cRGD augmented the antiglioma efficacy of Ad-REIC. These results may lead to a promising new approach for the treatment of malignant glioma.
- Published
- 2014
19. PIK3R1Met326Ile germline mutation correlates with cysteine-rich protein 61 expression and poor prognosis in glioblastoma
- Author
-
Atsuhito Uneda, Tomotsugu Ichikawa, Yasuhiko Hattori, Isao Date, Toshihiko Shimizu, Yoshihiro Otani, Joji Ishida, Yuji Matsumoto, Tetsuo Oka, Yusuke Tomita, Kazuhiko Kurozumi, Shuta Tomida, Hiroyuki Michiue, and Takehiro Matsubara
- Subjects
Adult ,Male ,0301 basic medicine ,Pathology ,medicine.medical_specialty ,Science ,Brain tumor ,Biology ,Article ,Germline ,Phosphatidylinositol 3-Kinases ,Young Adult ,03 medical and health sciences ,symbols.namesake ,Germline mutation ,Glioma ,medicine ,Humans ,Progression-free survival ,Germ-Line Mutation ,Survival analysis ,Aged ,Neoplasm Staging ,Aged, 80 and over ,Regulation of gene expression ,Sanger sequencing ,Multidisciplinary ,Brain Neoplasms ,Gene Expression Profiling ,High-Throughput Nucleotide Sequencing ,Sequence Analysis, DNA ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Progression-Free Survival ,Up-Regulation ,Class Ia Phosphatidylinositol 3-Kinase ,Gene Expression Regulation, Neoplastic ,030104 developmental biology ,Amino Acid Substitution ,Cancer research ,symbols ,Medicine ,Female ,Glioblastoma ,Cysteine-Rich Protein 61 - Abstract
Despite therapeutic advances, glioblastoma represents a lethal brain tumor. Recently, research to identify prognostic markers for glioblastoma has intensified. Our previous study demonstrated that median progression-free survival (PFS) and overall survival (OS) of patients with high cysteine-rich protein 61 (CCN1) expression was significantly shorter than that of patients with low CCN1 expression. To understand the molecular mechanisms that regulate CCN1 expression, we examined 147 tumour samples from 80 patients with glioblastoma and 67 patients with lower grade glioma. Next-generation and Sanger sequencing showed that PIK3R1Met326Ile was more frequent in the CCN1 high expression group (10/37 cases, 27.0%) than the CCN1 low expression group (3/38 cases, 7.9%) in glioblastoma. This mutation was also detected in corresponding blood samples. In multivariate analysis, high CCN1 expression and PIK3R1Met326Ile in glioblastoma patients were prognostic factors for OS [HR = 2.488 (1.298–4.769), p = 0.006] and [HR = 2.089 (1.020–4.277), p = 0.0439], respectively. Thus, the PIK3R1Met326Ile germline appears to be correlated with CCN1 expression and poor prognosis in glioblastoma.
- Published
- 2017
20. Simultaneous combination of electromagnetic navigation with visual evoked potential in endoscopic transsphenoidal surgery: clinical experience and technical considerations
- Author
-
Joji Ishida, Isao Date, Kazuhiko Kurozumi, and Masahiro Kameda
- Subjects
Adenoma ,Adult ,Male ,medicine.medical_specialty ,genetic structures ,medicine.medical_treatment ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Arachnoid cyst ,Monitoring, Intraoperative ,Sphenoid Bone ,Medicine ,Humans ,Pituitary Neoplasms ,Evoked potential ,Neuronavigation ,Neuroradiology ,Aged ,Transsphenoidal surgery ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Continuous monitoring ,Interventional radiology ,Middle Aged ,medicine.disease ,Endoscopy ,Surgery ,Arachnoid Cysts ,Neuroendoscopy ,Evoked Potentials, Visual ,Female ,Neurology (clinical) ,Neurosurgery ,Radiology ,business ,030217 neurology & neurosurgery - Abstract
The combination of electromagnetic navigation with continuous monitoring techniques allows for the best available anatomic and real-time functional intraoperative monitoring. Methodological aspects and technical adaptations for this combination of methods and the results from 19 patients with tumors in the pituitary region are reported. We retrospectively identified 19 patients who were treated with transsphenoidal surgery using high-resolution endoscopy (eTSS) at our hospital between June 2015 and June 2016. All patients underwent surgery under electromagnetic navigation with visual evoked potential (VEP) monitoring. The cases were reviewed for information on disease, and the distance between the patient tracker and emitter was measured. In 19 patients, 17 had pituitary adenomas, 1 had a Rathke cleft cyst, and 1 had an arachnoid cyst. The optimal distance between the patient tracker and emitter was 20–25 cm. VEP monitoring could be performed with unaffected recording quality under electromagnetic navigation. Also we were able to perform the registration and eTSS at this distance using both navigation and VEP monitoring. We performed eTSS for pituitary tumor by simultaneously using electromagnetic navigation and VEP. The optimal distance between the emitter and tracker minimizes VEP monitoring noise and allows accurate electromagnetic navigation.
- Published
- 2016
21. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus
- Author
-
Manabu Onishi, Kazuhiko Kurozumi, Ennio Antonio Chiocca, Joji Ishida, Tomotsugu Ichikawa, Balveen Kaur, Yosuke Shimazu, K. Fujii, and Isao Date
- Subjects
Cancer Research ,Combination therapy ,Angiogenesis ,Integrin ,Mice, Nude ,Cilengitide ,Pharmacology ,Article ,Receptors, G-Protein-Coupled ,Mice ,chemistry.chemical_compound ,Cell Movement ,In vivo ,Cell Line, Tumor ,glioma ,Glioma ,Chlorocebus aethiops ,Animals ,Humans ,Medicine ,Angiogenic Proteins ,Vero Cells ,Molecular Biology ,Oncolytic Virotherapy ,Tube formation ,Mice, Inbred BALB C ,biology ,Brain Neoplasms ,business.industry ,oncolytic viral therapy ,medicine.disease ,Combined Modality Therapy ,Immunohistochemistry ,Xenograft Model Antitumor Assays ,Peptide Fragments ,Oncolytic virus ,Oncolytic Viruses ,chemistry ,cilengitide ,biology.protein ,Molecular Medicine ,business ,Snake Venoms - Abstract
Oncolytic viral (OV) therapy has been considered as a promising treatment modality for brain tumors. Vasculostatin, the fragment of brain-specific angiogenesis inhibitor-1, shows anti-angiogenic activity against malignant gliomas. Previously, a vasculostatin-expressing oncolytic herpes simplex virus-1, Rapid Antiangiogenesis Mediated By Oncolytic virus (RAMBO), was reported to have a potent antitumor effect. Here, we investigated the therapeutic efficacy of RAMBO and cilengitide, an integrin inhibitor, combination therapy for malignant glioma. In vitro, tube formation was significantly decreased in RAMBO and cilengitide combination treatment compared with RAMBO or cilengitide monotherapy. Moreover, combination treatment induced a synergistic suppressive effect on endothelial cell migration compared with the control virus. RAMBO, combined with cilengitide, induced synergistic cytotoxicity on glioma cells. In the caspase-8 and -9 assays, the relative absorption of U87 Delta EGFR cell clusters treated with cilengitide and with RAMBO was significantly higher than that of those treated with control. In addition, the activity of caspase 3/7 was significantly increased with combination therapy. In vivo, there was a significant increase in the survival of mice treated with combination therapy compared with RAMBO or cilengitide monotherapy. These results indicate that cilengitide enhanced vasculostatin-expressing OV therapy for malignant glioma and provide a rationale for designing future clinical trials combining these two agents.
- Published
- 2013
22. A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy
- Author
-
Yusuke Tomita, Masakiyo Sakaguchi, Masami Watanabe, Tetsuo Oka, Hiromi Kumon, Yasutomo Nasu, Joji Ishida, Kazuhiko Kurozumi, Isao Date, Tomotsugu Ichikawa, Yosuke Shimazu, Yoshihiro Otani, and Toshihiko Shimizu
- Subjects
0301 basic medicine ,Genetic enhancement ,Genetic Vectors ,Apoptosis ,Biology ,medicine.disease_cause ,Article ,Viral vector ,Adenoviridae ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Multiplicity of infection ,Glioma ,Cell Line, Tumor ,Gene expression ,medicine ,Animals ,Humans ,Adaptor Proteins, Signal Transducing ,Regulation of gene expression ,Multidisciplinary ,Genetic Therapy ,medicine.disease ,Molecular biology ,Xenograft Model Antitumor Assays ,Gene Expression Regulation, Neoplastic ,Disease Models, Animal ,030104 developmental biology ,Cell culture ,030220 oncology & carcinogenesis ,Intercellular Signaling Peptides and Proteins ,Chemokines - Abstract
Reduced expression in immortalized cells/Dickkopf-3 (REIC/Dkk-3) is a tumor suppressor and therapeutic gene in many human cancers. Recently, an adenovirus REIC vector with the super gene expression system (Ad-SGE-REIC) was developed to increase REIC/Dkk-3 expression and enhance therapeutic effects compared with the conventional adenoviral vector (Ad-CAG-REIC). In this study, we investigated the in vitro and in vivo effects of Ad-SGE-REIC on malignant glioma. In U87ΔEGFR and GL261 glioma cells, western blotting confirmed that robust upregulation of REIC/Dkk-3 expression occurred in Ad-SGE-REIC-transduced cells, most notably after transduction at a multiplicity of infection of 10. Cytotoxicity assays showed that Ad-SGE-REIC resulted in a time-dependent and significant reduction in the number of malignant glioma cells attaching to the bottom of culture wells. Xenograft and syngeneic mouse intracranial glioma models treated with Ad-SGE-REIC had significantly longer survival than those treated with the control vector Ad-LacZ or with Ad-CAG-REIC. This study demonstrated the anti-glioma effect of Ad-SGE-REIC, which may represent a promising strategy for the treatment of malignant glioma.
- Published
- 2016
23. Adhesion molecules and the extracellular matrix as drug targets for glioma
- Author
-
Tomotsugu Ichikawa, Toshihiko Shimizu, Isao Date, Kazuhiko Kurozumi, and Joji Ishida
- Subjects
0301 basic medicine ,Drug ,Cancer Research ,Pathology ,medicine.medical_specialty ,Angiogenesis ,media_common.quotation_subject ,Angiogenesis Inhibitors ,Biology ,Tumor vasculature ,Antibodies ,Extracellular matrix ,03 medical and health sciences ,0302 clinical medicine ,Glioma ,medicine ,Humans ,Neoplasm Invasiveness ,Molecular Targeted Therapy ,media_common ,Cell invasion ,Neovascularization, Pathologic ,Cell adhesion molecule ,Brain Neoplasms ,Disease progression ,General Medicine ,medicine.disease ,White Matter ,Cell biology ,Extracellular Matrix ,Thalidomide ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Disease Progression ,Neurology (clinical) ,Cell Adhesion Molecules ,Snake Venoms - Abstract
The formation of tumor vasculature and cell invasion along white matter tracts have pivotal roles in the development and progression of glioma. A better understanding of the mechanisms of angiogenesis and invasion in glioma will aid the development of novel therapeutic strategies. The processes of angiogenesis and invasion cause the production of an array of adhesion molecules and extracellular matrix (ECM) components. This review focuses on the role of adhesion molecules and the ECM in malignant glioma. The results of clinical trials using drugs targeted against adhesion molecules and the ECM for glioma are also discussed.
- Published
- 2016
24. Induction of WNT11 by hypoxia and hypoxia-inducible factor-1α regulates cell proliferation, migration and invasion
- Author
-
Sadeesh K. Ramakrishnan, Joji Ishida, Kazuhiko Kurozumi, Xiaomin Ning, Xiang Xue, Katherine A. Overmyer, Michael A. Reid, Yatrik M. Shah, Yao Yao, Ormond A. MacDougald, William P. Cawthorn, Matthew Taylor, Hiroyuki Mori, and Brian S. Learman
- Subjects
0301 basic medicine ,Vascular Endothelial Growth Factor A ,Aryl hydrocarbon receptor nuclear translocator ,Angiogenesis ,Angiogenesis Inhibitors ,Biology ,Article ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,Cell Movement ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Neoplasm Invasiveness ,Cell Proliferation ,Mice, Knockout ,Multidisciplinary ,Tumor hypoxia ,Neovascularization, Pathologic ,Aryl Hydrocarbon Receptor Nuclear Translocator ,Glioma ,Hypoxia (medical) ,Hypoxia-Inducible Factor 1, alpha Subunit ,Cell Hypoxia ,3. Good health ,Vascular endothelial growth factor ,Bevacizumab ,Gene Expression Regulation, Neoplastic ,Mice, Inbred C57BL ,Oxygen ,Wnt Proteins ,Vascular endothelial growth factor A ,030104 developmental biology ,Hypoxia-inducible factors ,chemistry ,Von Hippel-Lindau Tumor Suppressor Protein ,Protein Biosynthesis ,Immunology ,Cancer research ,Tumor promotion ,sense organs ,medicine.symptom ,HeLa Cells - Abstract
Changes in cellular oxygen tension play important roles in physiological processes including development and pathological processes such as tumor promotion. The cellular adaptations to sustained hypoxia are mediated by hypoxia-inducible factors (HIFs) to regulate downstream target gene expression. With hypoxia, the stabilized HIF-α and aryl hydrocarbon receptor nuclear translocator (ARNT, also known as HIF-β) heterodimer bind to hypoxia response elements (HREs) and regulate expression of target genes. Here, we report that WNT11 is induced by hypoxia in many cell types, and that transcription of WNT11 is regulated primarily by HIF-1α. We observed induced WNT11 expression in the hypoxic area of allograft tumors. In addition, in mice bearing orthotopic malignant gliomas, inhibition with bevacizumab of vascular endothelial growth factor, which is an important stimulus for angiogenesis, increased nuclear HIF-1α and HIF-2α, and expression of WNT11. Gain- and loss-of-function approaches revealed that WNT11 stimulates proliferation, migration and invasion of cancer-derived cells, and increases activity of matrix metalloproteinase (MMP)-2 and 9. Since tumor hypoxia has been proposed to increase tumor aggressiveness, these data suggest WNT11 as a possible target for cancer therapies, especially for tumors treated with antiangiogenic therapy.
- Published
- 2016
25. Hybrid Microscopic-Endoscopic Surgery for Craniopharyngioma in Neurosurgical Suite: Technical Notes
- Author
-
Yoshihiro Otani, Isao Date, Kazuhiko Kurozumi, Joji Ishida, Kentaro Fujii, Shigeki Ono, and Tomotsugu Ichikawa
- Subjects
Male ,Microsurgery ,medicine.medical_specialty ,Neoplasm, Residual ,Endoscope ,Vomiting ,medicine.medical_treatment ,Vision Disorders ,Pituitary neoplasm ,Neurosurgical Procedures ,Craniopharyngioma ,03 medical and health sciences ,0302 clinical medicine ,Monitoring, Intraoperative ,medicine ,Humans ,Pituitary Neoplasms ,Child ,Third ventricle ,business.industry ,Blind spot ,Headache ,medicine.disease ,Magnetic Resonance Imaging ,Body Height ,Surgery ,Treatment Outcome ,medicine.anatomical_structure ,Neuroendoscopy ,Child, Preschool ,030220 oncology & carcinogenesis ,Female ,Neurology (clinical) ,Neurosurgery ,Visual Fields ,business ,030217 neurology & neurosurgery - Abstract
Objective The best chance of curing craniopharyngioma is achieved by microsurgical total resection; however, its location adjacent to critical structures hinders complete resection without neurologic deterioration. Unrecognized residual tumor within microscopic blind spots might result in tumor recurrences. To improve outcomes, new techniques are necessary to visualize tissue within these blind spots. We examined the success of hybrid microscopic-endoscopic neurosurgery for craniopharyngioma in a neurosurgical suite. Methods Four children with craniopharyngiomas underwent microscopic resection. When the neurosurgeon was confident that most of the visible tumor was removed but was suspicious of residual tumor within the blind spot, he or she used an integrated endoscope-holder system to inspect and remove any residual tumor. Two ceiling monitors were mounted side by side in front of the surgeon to display both microscopic and endoscopic views and to view both monitors simultaneously. Results Surgery was performed in all patients via the frontobasal interhemispheric approach. Residual tumors were observed in the sella (2 patients), on the ventral surface of the chiasm and optic nerve (1 patient), and in the third ventricle (1 patient) and were resected to achieve total resection. Postoperatively, visual function was improved in 2 patients and none exhibited deterioration related to the surgery. Conclusions Simultaneous microscopic and endoscopic observation with the use of dual monitors in a neurosurgical suite was ergonomically optimal for the surgeon to perform microsurgical procedures and to avoid traumatizing surrounding vessels or neural tissues. Hybrid microscopic-endoscopic neurosurgery may contribute to safe, less-invasive, and maximal resection to achieve better prognosis in children with craniopharyngioma.
- Published
- 2016
26. [Usefulness of endovascular treatment for delayed massive epistaxis following endoscopic endonasal transsphenoidal surgery: a case report]
- Author
-
Tetsuo, Oka, Kenji, Sugiu, Joji, Ishida, Tomohito, Hishikawa, Shigeki, Ono, Koji, Tokunaga, and Isao, Date
- Subjects
Adenoma ,Male ,Epistaxis ,Postoperative Complications ,Sphenoid Sinus ,Endovascular Procedures ,Humans ,Pituitary Neoplasms ,Embolization, Therapeutic ,Aged - Abstract
We report here a case of massive nasal bleeding from the sphenopalatine artery three weeks after endonasal transsphenoidal surgery. This 66-year-old male suffered from massive nasal bleeding with the status of hypovolemic shock. Under general anesthesia, an emergent angiography revealed an extravasation from the sphenopalatine artery. Trans-arterial embolization using coil and n-butyl-cyanoacrylate (NBCA) was performed following the diagnostic angiography. Complete occlusion of the injured artery was achieved. The patient showed good recovery from general anesthesia. Delayed nasal bleeding after endonasal transsphenoidal surgery is a rare but important complication. The sphenopalatine artery and its branch are located in the hidden inferior lateral corner of the sphenoid sinus and may be injured during enlargement of the sphenoid opening. When massive delayed nasal bleeding follows transsphenoidal surgery and damage of the internal carotid artery has been ruled out, endovascular treatment of the external carotid artery should be considered.
- Published
- 2012
27. ANNEXIN A2 REGULATES ANGIOGENESIS AND INVASION PHENOTYPES OF MALIGNANT GLIOMA
- Author
-
Satoshi Inoue, Joji Ishida, Koichi Yoshida, Yoshihiro Otani, Tomotsugu Ichikawa, Kazuhiko Kurozumi, Hiroyuki Michiue, E. Antonio Chiocca, Yosuke Shimazu, Manabu Onishi, Isao Date, Kentaro Fujii, and Tomoko Maruo
- Subjects
Vascular Endothelial Growth Factor A ,Cancer Research ,Pathology ,medicine.medical_specialty ,Platelet-derived growth factor ,Angiogenesis ,medicine.medical_treatment ,Gene Expression ,Biology ,abstracts ,Neovascularization ,chemistry.chemical_compound ,Diffuse Glioma ,Annexin ,Glioma ,Cell Adhesion ,medicine ,Animals ,Humans ,Neoplasm Invasiveness ,Annexin A2 ,Cells, Cultured ,Platelet-Derived Growth Factor ,Neovascularization, Pathologic ,Brain Neoplasms ,Growth factor ,Endothelial Cells ,General Medicine ,medicine.disease ,Molecular biology ,Rats, Inbred F344 ,Vascular endothelial growth factor ,Disease Models, Animal ,Vascular endothelial growth factor A ,Oncology ,chemistry ,biology.protein ,Immunohistochemistry ,Female ,Neurology (clinical) ,medicine.symptom ,Platelet-derived growth factor receptor - Abstract
BACKGROUND: Despite advances in multimodal therapy, patients with malignant glioma have a dismal prognosis. Aberrant angiogenesis and diffuse glioma cell invasion are major obstacles for effective treatment. Therefore, investigation of angiogenesis and invasion is essential for the development of a curative therapy. We established animal models that histologically mimic two invasive and angiogenic phenotypes of glioma, ie, angiogenesis-dependent invasion (J3T-1) and angiogenesis-independent invasion (J3T-2). In our previous study, comparative proteomic analysis showed that annexin A2 was more highly expressed in J3T-1 than in J3T-2. In this study, the function of annexin A2 in malignant glioma in relation to angiogenesis and invasion was investigated using these animal models. METHODS: Annexin A2-downregulated J3T-1 cells (J3T-1shA) and annexin A2-upregulated J3T-2 cells (J3T-2A) were generated by gene transfection. Quantitative reverse transcription polymerase chain reaction (QRT-PCR) and immunohistochemical staining of annexin A2 and vascular endothelial growth factor (VEGF) were performed on cultured cells. J3T-1, J3T-1shA, J3T-2, and J3T-2A brain tumors were established in athymic rats. Brain sections were evaluated histopathologically. Human glioblastoma specimens were stained for annexin A2, VEGF, and platelet-derived growth factor (PDGF). RESULTS: QRT-PCR and immunohistochemical staining of cultured cells revealed that expression of VEGF was upregulated in accordance with the expression of annexin A2 in J3T-1 and J3T-2A cells. J3T-1 tumors showed remarkable angiogenic activity and invasion around neovasculature, whereas J3T-1shA tumors, including J3T-2 tumors, showed no angiogenic activity, but diffuse single-cell infiltration of tumor cells into normal parenchyma. J3T-2A tumors were highly angiogenic and showed angiogenesis-dependent invasion. Human glioblastoma specimens revealed that annexin A2 was positive in clusters of tumor cells around dilated vessels (25/30 cases). The intensity of VEGF and PDGF staining corresponded to the expression of annexin A2 (correlation coefficients: annexin A2/VEGF: R = 0.73, P < 0.05; annexin A2/PDGF: R = 0.37, P < 0.05). CONCLUSIONS: Our results revealed that the phenotype of glioma invasion is closely related to angiogenesis, and annexin A2 is one of the factors that regulates angiogenesis and invasion phenotype of malignant glioma. SECONDARY CATEGORY: Neuropathology & Tumor Biomarkers.
- Published
- 2014
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.